Literature DB >> 25657489

Knowledge and perception of human papilloma virus vaccine among the antenatal women in a Nigerian tertiary hospital.

Teddy E Agida1, Godwin O Akaba1, Aliyu Y Isah1, Bissalla Ekele1.   

Abstract

BACKGROUND: Cervical cancer is a major health problem globally, especially in sub-Saharan Africa, Nigeria inclusive. One of the preventive measures is the vaccination of teenagers against oncogenic human papilloma virus. The aim of this study was to find out the level of knowledge mothers possess about these vaccines and their willingness to administer vaccination to their teenage girls.
MATERIALS AND METHODS: This was a cross-sectional descriptive study of 255 consecutive women attending antenatal clinic at the University of Abuja Teaching Hospital, Abuja. They were given either a self-administered questionnaire or interviewer-administered questionnaire containing both closed and open-ended questions. Information recorded includes socio-demographic variables, knowledge of cervical cancer, knowledge of HPV/HPV vaccines and acceptance of these vaccines for their adolescent girls. The data was analysed using descriptive statistics.
RESULTS: The mean age of the respondents was 26.9 years. Over 90% had at least secondary education. A total of 102 (40%) had the knowledge of cancer of the cervix while 153 (60%) had never heard about it. Overall, 236 (92.5%) of them had no idea about the predisposing factors. The study showed that only 23 (9.0%) out of the total respondents had heard about human papilloma virus (HPV) infection. In the same vein, 20 (7.8%) had knowledge about HPV vaccine. Among the respondents, who had the knowledge of HPV and vaccination, 18.2% and 23.4% of them had secondary and tertiary levels of education respectively. Overall, 160 (62.8%) accepted that the vaccines could be administered to their teenage girls.
CONCLUSIONS: Awareness of cervical cancer, HPV infections, and HPV vaccines is low among antenatal clinic attendees in Gwagwalada, Abuja. However, majority of them would want their girls vaccinated against HPV infections. There is a need for all stakeholders to step up awareness creation for improved HPV vaccination project in Nigeria.

Entities:  

Keywords:  Antenatal clinic attendees; HPV infections; awareness; cancer; cervical cancer; cervix; vaccines

Year:  2015        PMID: 25657489      PMCID: PMC4314855          DOI: 10.4103/0300-1652.149166

Source DB:  PubMed          Journal:  Niger Med J        ISSN: 0300-1652


INTRODUCTION

Cervical Cancer is a major public health problem globally. Over 560,000 new cases and about 275,000 deaths are recorded each year, with more than 55% occurring in developing countries.1 It is the most common gynaecological cancer among women in sub-Saharan Africa.2 It is estimated that 70,722 new cases of invasive cervical cancer occur annually in sub-Saharan Africa.3 Nigeria is the most populous country in Africa with approximately 173 million people.4 The incidence rate of cervical cancer in Nigeria was reported to be 25/100,000 per year, which translates to a disease burden for an estimated 32 million women in 2005 to about 8000 cases per year.5 Current estimates indicate that cervical cancer ranks as the second most frequent cancer among women in Nigeria.6 Every year, 14089 women are diagnosed with cervical cancer.6 High burden of cervical cancer has been reported in Nigeria's Federal Capital City, Abuja.7 Epidemiological, molecular and clinical evidences have shown that cervical cancer is caused by human papilloma virus, a sexually transmitted infection, especially serotype 6, 11, 16 and 18.89101112131415 Human papilloma virus infection is common in Nigeria. A study in Ibadan showed an overall prevalence of 26.3% while the prevalence among women without cervical lesions was 24.8%.16 Currently, it is estimated that about 23.7% of women in general population in Nigeria harbour cervical HPV infection at a time.6 In view of the high burden of cervical cancer, various means of prevention should be encouraged. One way of primary prevention is through vaccination against oncogenic HPV types.9141718 Currently, there are two vaccines that have been approved by the U.S. Food and Drug Administration (FDA). These are the bivalent HPV vaccine (Cervarix)) and the quadrivalent HPV vaccine (Gardasil).18 Both have been found to be nearly 100% effective in preventing cervical intraepithelial neoplasia 2 (CIN 2), CIN 3, and condylomatous vulvar disease related to the HPV genotypes covered by the vaccines.19202122 The vaccines are approved for administration to females aged 9-26 years.111418 The vaccines were licensed and introduced in Nigeria in 2009, but they are being utilised by a few privileged population.2324 Studies have shown that the knowledge of HPV infection and vaccine against the infection is quite low and if available, the cost is beyond the reach of average Nigerians.23252627 Despite the high prevalence of cervical cancer and HPV infection in Nigeria, utilisation of HPV vaccine, which is one of the cardinal preventive measures is low.23242526 Whereas majority of the studies on the knowledge and perception of HPV vaccine were from the southern part of Nigeria,23242526 but there is a need to find out how much knowledge mothers have about HPV infection and immunisation against it in Nigeria's Federal Capital Territory. This is necessary since the vaccine should be administered from the age of 9 years. Parents therefore, need to be informed about the features of each vaccine so that the decision to choose one over the other is made with informed consent.28 Mothers may express fears about safety of the vaccines and so may not provide written consent for their daughters to have the vaccine.29 This study, therefore, was aimed at finding out how much knowledge mothers have about these vaccines and the acceptance for their adolescent girls to be vaccinated since the mothers are close to the girls at this stage and can help in decision-making for them.

MATERIALS AND METHODS

This was a cross-sectional descriptive study of 255 consecutive women attending antenatal clinic at the University of Abuja Teaching Hospital, Abuja. The hospital is a 350-bedded referral Federal Government tertiary. Data was collected between the months of March and April 2013. Approval for the study was obtained from the Research Ethics Committee of the Hospital. Informed consent was obtained from the women and they were given self-administered, 18-item questionnaire with both closed and open-ended questions. For those who were unable to understand the questionnaire very well or illiterate, the interviewer-administered questionnaire was used. The questionnaire had four main sections: Socio-demographic variables, knowledge of cervical cancer, knowledge of HPV/HPV vaccines and acceptance of these vaccines for their adolescent girls. The data was analysed using descriptive statistics.

RESULTS

There were 255 respondents recruited for the study. Their mean age was 26.9 years. Table 1 shows there were more respondents within the age bracket of 25-29 years. Majority of the respondents (32.2%) were civil servants, whereas 22.3% of them were full-time housewives (they were not involved in any gainful employment). Majority (74.3%) were multiparous women of paras 1-4. About 89.4% of the respondents had at least secondary level of education (30.6% secondary, 58.8% tertiary).
Table 1

Sociodemographic characteristics

Sociodemographic characteristics One hundred and two (40%) had knowledge about cancer of the cervix while 153 (60%) had never heard about the vaccine [Table 2]. Table 2 also shows that overall, 236 (92.5%) of the respondents had no idea about the predisposing factors while 19 (7.5%) could mention one or more predisposing factors. This section of respondents comprise to 18.6% who had the knowledge of cervical cancer.
Table 2

Knowledge of cervical cancer

Knowledge of cervical cancer Table 3 shows that 23 (9.0%) responders have heard about HPV infection while 232 (91%) had not. Out of the 23 respondents, 19 had knowledge that it is sexually transmitted, while 4 had heard that it can cause cancer of the cervix. Overall, 7.5% and 5.5% of the total respondents knew that it is sexually transmitted and can cause cancer of the cervix respectively. Only 20 (7.8%) out of the total respondents had knowledge about HPV vaccine.
Table 3

Knowledge of HPV/HPV vaccine

Knowledge of HPV/HPV vaccine When educational status was compared with knowledge of HPV and vaccination amongst the respondents, 18.2% respondents comprised of those who had the knowledge of cancer of the cervix with no formal education and those who had no knowledge with primary level of education and 23.4% of respondents of those with secondary and tertiary level of education had the knowledge of HPV infection and the vaccines. When asked if they would recommend the vaccines to be given to their daughters as shown in Table 4, 160 (62.8%) said yes, 48 (18.8%) said no while 47 (18.4%) were indifferent. Those who said no gave reasons bothering on ignorance, fear of side effects and possibility of the vaccines affecting future fertility.
Table 4

Recommend it to your daughter?

Recommend it to your daughter?

DISCUSSION

This study highlights the awareness and perception of mothers about HPV/HPV vaccination in our community. The fact that about 30.6% of the respondents had secondary school education and 58.8% had tertiary level of education meant that their literacy level was high. Inspite of this, awareness of cancer of cervix and HPV infection amongst them was low. This finding is similar to that from a community based pilot survey in Gwagwalada Area Council in the Federal Capital Territory, Abuja, where very small proportion of respondents knew about the disease.27 However, about 63% of the participants in that study were educated up to primary school level, whereas about 90% of the respondents in this study had secondary and tertiary levels of education. One would have thought that awareness of this disease should have been higher amongst them. This is in contrast to community studies carried out in Lagos and Ibadan, respectively, wherein it was discovered that awareness of cancer of cervix was very high.2325 While awareness of HPV disease in the Ibadan study was very high,23 in Lagos, it was very low.25 In a similar study in Kuala Lumpur, Malaysia, over 50% of mothers were aware of cancer of cervix and HPV diseases.29 The implication of this is that if mothers who are educated lack adequate knowledge of a disease that is very prevalent in our community, then a lot has to be done to enlighten them to talk about prevention. Health promotion strategies to educate the public about prevention of STIs of public health significance can be effective in preventing genital HPV infection.17 Primary prevention of cervical cancer can be achieved through prevention and control of genital infection with oncogenic HPV types.17 One of the methods of prevention is by vaccinating teenage girls with HPV vaccine. Mothers play crucial roles in making informed decision for their daughters. This study and similar studies from this country have shown that awareness of HPV vaccine is very low.232526 This is worrisome because, for there to be effective coverage of HPV vaccination for the teenage groups, we need parental acceptance of the vaccines.101428 There cannot be parental acceptance if the mothers don't have adequate knowledge and are not aware of it. Even though these vaccines were licensed and introduced into this country in 2009,23 they were only launched by the Federal Government in 2011 and only 6 pilot centres are currently commissioned to give HPV vaccines, apart from that offered by private facilities.25 These facilities will be under utilised when there is low awareness about this preventive measure among those who are supposed to make decisions on behalf of the teenage girls. Many parents think that HPV vaccination is not needed and are concerned about safety and adverse reactions.30 Some parents also have concern that HPV vaccination may cause an increase in sexual activity among adolescents.18 Adequate information therefore needs to be provided to the parents to dispel all these concerns. Despite the low awareness of these vaccines, acceptability for their daughters to be vaccinated was high. Other studies from this country and Malaysia showed similar findings.232529 According to the CDC, if healthcare providers increase HPV vaccination coverage to 80%, it is estimated that an additional 53,000 cases of cervical cancer could be prevented during the life time of those younger than 12 years.31 Furthermore, for every year that coverage does not increase, an additional 4,400 women will develop cervical cancer.31 These data highlight the overwhelming importance of HPV vaccination efforts, including discussions with parents of children and adolescents about the benefits of HPV immunisation for cancer prevention.31 In conclusion, awareness of cancer of the cervix, HPV infections and HPV vaccine is low among antenatal clinic attendees in Gwagwalada, Abuja. In addition to screening, HPV vaccination of our young girls will go a long way in prevention. Since the acceptability of the vaccines for their adolescent girls is high amongst the respondents, scaling up of nationally organised HPV vaccination and low cost screening programmes subsidised by funding from government and donor agencies are key to this intervention.3233 One way of getting subsidy is through the Global Alliance for Vaccines and Immunizations (GAVI) projects.333435 It is estimated that if subsidised by the GAVI Alliance, the vaccine could reach over 80% of the countries in sub-Saharan Africa.2 Effective awareness creation amongst the parents especially mothers, is therefore, very germane in HPV vaccination project in Nigeria.

Limitations

Explaining HPV infection to the few who were non-literate was quite a challenge. However, a good number of them had knowledge about other STIs, but when the explanation was zeroed down to HPV, they simply said they had never heard of it.
  25 in total

1.  National HPV immunisation programme: knowledge and acceptance of mothers attending an obstetrics clinic at a teaching hospital, Kuala Lumpur.

Authors:  Sharifa Wan Puteh Ezat; Rozita Hod; Jamsiah Mustafa; Ahmad Zailani Hatta Mohd Dali; Aqmar Suraya Sulaiman; Azlin Azman
Journal:  Asian Pac J Cancer Prev       Date:  2013

Review 2.  Part I: Cancer in Indigenous Africans--burden, distribution, and trends.

Authors:  D Max Parkin; Freddy Sitas; Mike Chirenje; Lara Stein; Raymond Abratt; Henry Wabinga
Journal:  Lancet Oncol       Date:  2008-07       Impact factor: 41.316

3.  Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.

Authors:  Basil Donovan; Neil Franklin; Rebecca Guy; Andrew E Grulich; David G Regan; Hammad Ali; Handan Wand; Christopher K Fairley
Journal:  Lancet Infect Dis       Date:  2010-11-08       Impact factor: 25.071

4.  Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Authors:  Nubia Muñoz; Susanne K Kjaer; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricía J Garcia; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Marc Steben; F Xavier Bosch; Joakim Dillner; Warner K Huh; Elmar A Joura; Robert J Kurman; Slawomir Majewski; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine T Bryan; Lisa C Lupinacci; Katherine E D Giacoletti; Heather L Sings; Margaret K James; Teresa M Hesley; Eliav Barr; Richard M Haupt
Journal:  J Natl Cancer Inst       Date:  2010-02-05       Impact factor: 13.506

5.  Committee opinion no. 588: human papillomavirus vaccination.

Authors: 
Journal:  Obstet Gynecol       Date:  2014-03       Impact factor: 7.661

Review 6.  A systematic review of randomized trials assessing human papillomavirus testing in cervical cancer screening.

Authors:  Insiyyah Y Patanwala; Heidi M Bauer; Justin Miyamoto; Ina U Park; Megan J Huchko; Karen K Smith-McCune
Journal:  Am J Obstet Gynecol       Date:  2012-11-15       Impact factor: 8.661

7.  Epidemiological characteristics of carcinoma of the cervix in the Federal capital Territory of Nigeria.

Authors:  A C Umezulike; S N Tabansi; H A S Ewunonu; E J C Nwana
Journal:  Niger J Clin Pract       Date:  2007-06       Impact factor: 0.968

8.  Delivery cost of human papillomavirus vaccination of young adolescent girls in Peru, Uganda and Viet Nam.

Authors:  Carol E Levin; Hoang Van Minh; John Odaga; Swampa Sarit Rout; Diep Nguyen Thi Ngoc; Lysander Menezes; Maria Ana Mendoza Araujo; D Scott LaMontagne
Journal:  Bull World Health Organ       Date:  2013-06-19       Impact factor: 9.408

9.  Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-07-26       Impact factor: 17.586

10.  Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study.

Authors:  J O Thomas; R Herrero; A A Omigbodun; K Ojemakinde; I O Ajayi; A Fawole; O Oladepo; J S Smith; A Arslan; N Muñoz; P J F Snijders; C J L M Meijer; S Franceschi
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640

View more
  7 in total

1.  Poor Knowledge of Human Papilloma Virus and Vaccination Among Respondents from Three Nigerian States.

Authors:  Angela O Eni; Mojisola G Soluade; Oghenevwairhe P Efekemo; Titilayo T Igwe; Olabode A Onile-Ere
Journal:  J Community Health       Date:  2018-12

2.  Awareness, acceptability and uptake of cervical cancer vaccination services among female secondary school teachers in Enugu, Nigeria: a cross-sectional study.

Authors:  Joseph Tochukwu Enebe; Nympha Onyinye Enebe; Chuka Chike Agunwa; Obinna Chukwuebuka Nduagubam; Innocent Igwebeze Okafor; Elias Chike Aniwada; Emmanuel Nwabueze Aguwa
Journal:  Pan Afr Med J       Date:  2021-05-21

Review 3.  Human papillomavirus and cervical cancer.

Authors:  Kehinde Sharafadeen Okunade
Journal:  J Obstet Gynaecol       Date:  2019-09-10       Impact factor: 1.246

4.  Awareness of cervical cancer and willingness to be vaccinated against human papillomavirus in Mozambican adolescent girls.

Authors:  Azucena Bardají; Carolina Mindu; Orvalho J Augusto; Aina Casellas; Olga Cambaco; Egas Simbine; Graça Matsinhe; Eusébio Macete; Clara Menéndez; Esperança Sevene; Khátia Munguambe
Journal:  Papillomavirus Res       Date:  2018-04-14

Review 5.  Cervical Cancer and Human Papillomavirus Vaccine Knowledge, Utilisation, Prevention Educational Interventions and Policy Response in Nigeria: A Scoping Review.

Authors:  Yetunde O John-Akinola; Chizoma M Ndikom; Mojisola M Oluwasanu; Temitayo Adebisi; Oluwaponmile Odukoya
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

6.  Knowledge and Acceptability of Human Papillomavirus Vaccination among Women Attending the Gynaecological Outpatient Clinics of a University Teaching Hospital in Lagos, Nigeria.

Authors:  Kehinde S Okunade; Oyebola Sunmonu; Gbemisola E Osanyin; Ayodeji A Oluwole
Journal:  J Trop Med       Date:  2017-12-19

7.  Reducing incidence of cervical cancer: knowledge and attitudes of caregivers in Nigerian city to human papilloma virus vaccination.

Authors:  Adaobi I Bisi-Onyemaechi; Ugo N Chikani; Obinna Nduagubam
Journal:  Infect Agent Cancer       Date:  2018-08-17       Impact factor: 2.965

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.